Marc Goodman
Stock Analyst at Leerink Partners
(2.95)
# 1,392
Out of 5,127 analysts
94
Total ratings
58.67%
Success rate
29%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $17.19 | +74.52% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.73 | +189.02% | 1 | Nov 17, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Market Perform | $19 | $21.48 | -13.87% | 3 | Oct 23, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $20.80 | +63.46% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $11.36 | +340.14% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $11.83 | -15.47% | 5 | May 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $167.55 | -10.47% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.43 | -77.43% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $15.24 | +109.97% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $164.01 | -84.76% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $17.07 | +192.91% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $5.74 | +248.43% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $135.57 | -15.17% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $186.00 | +66.67% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $41.22 | +11.60% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $26.91 | -21.96% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $160.25 | +31.05% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.44 | +190.70% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $29.60 | -8.78% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $4.18 | +258.85% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $657.46 | -58.93% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $224.13 | -57.17% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $55.90 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $110.99 | -39.63% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $14.70 | +566.67% | 7 | Oct 5, 2017 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $17.19
Upside: +74.52%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.73
Upside: +189.02%
Avadel Pharmaceuticals
Oct 23, 2025
Downgrades: Market Perform
Price Target: $19
Current: $21.48
Upside: -13.87%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $20.80
Upside: +63.46%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $11.36
Upside: +340.14%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $11.83
Upside: -15.47%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $167.55
Upside: -10.47%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.43
Upside: -77.43%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $15.24
Upside: +109.97%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $164.01
Upside: -84.76%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $17.07
Upside: +192.91%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $5.74
Upside: +248.43%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $135.57
Upside: -15.17%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $186.00
Upside: +66.67%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $41.22
Upside: +11.60%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $26.91
Upside: -21.96%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $160.25
Upside: +31.05%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.44
Upside: +190.70%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $29.60
Upside: -8.78%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.18
Upside: +258.85%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $657.46
Upside: -58.93%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $224.13
Upside: -57.17%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $55.90
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $110.99
Upside: -39.63%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $14.70
Upside: +566.67%